# A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Source: https://onco.cc/trials/nct06485219/  
OnCo record `nct06485219` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Purinostat in peripheral T-cell lymphomas, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.

## Summary

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma is a phase 2 interventional study registered as NCT06485219 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 50 participants enrolled, started 2024-04-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: 11.2 mg/m2 Purinostat Mesylate and 15 mg/m2 Purinostat Mesylate.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06485219
- Phase: 2
- Setting: An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Purinostat Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06485219: https://clinicaltrials.gov/study/NCT06485219

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Purinostat](https://onco.cc/drugs/purinostat/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct06485219.json